Jamshedpur Reporter

DelveInsight’s “Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cancer Vaccines market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Vaccines Market Forecast

Some of the key facts of the Cancer Vaccines Market Report:

• The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In May 2026, Guardant Health announced that the U.S. FDA has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). Developed collaboratively by Arvinas and Pfizer, VEPPANU is indicated for adults with estrogen receptor-positive (ER+), HER2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer, identified through an FDA-authorized diagnostic test, whose disease has progressed after receiving at least one prior endocrine therapy.

• In May 2026, The FDA has granted approval to vepdegestrant (Veppanu) for the treatment of patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as identified through an FDA-authorized diagnostic test, according to an official agency announcement. In addition, the FDA approved the Guardant360 CDx companion diagnostic to aid in detecting ESR1 mutations in eligible patients. The approval decision was supported by findings from the Phase 3 VERITAC-2 trial (NCT05654623), which evaluated vepdegestrant as a monotherapy for patients with advanced metastatic breast cancer.

• In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01.

• In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries.

• In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000.

• Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK.

• The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more.

• Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others

• Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others

• Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation

• The Cancer Vaccines market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics.

Cancer Vaccines Overview

Cancer vaccines are a type of immunotherapy designed to stimulate the body’s immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence.

Get a Free sample for the Cancer Vaccines Market Report:

https://www.delveinsight.com/report-store/cancer-vaccines-market

Cancer Vaccines Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cancer Vaccines Epidemiology Segmentation:

The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Cancer Vaccines

• Prevalent Cases of Cancer Vaccines by severity

• Gender-specific Prevalence of Cancer Vaccines

• Diagnosed Cases of Episodic and Chronic Cancer Vaccines

Download the report to understand which factors are driving Cancer Vaccines epidemiology trends @ Cancer Vaccines Epidemiology Forecast

Cancer Vaccines Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cancer Vaccines Therapies and Key Companies

• PROVENGE (sipuleucel-T): Dendreon Pharmaceuticals

• CAN-2409: Candel Therapeutics

• LB-LR1109: LG Chem and AVEO Oncology

• DCVax-L: Northwest Biotherapeutics

• IO102-IO103: IO Biotech

• ITI-1000: Immunomic Therapeutics

• EVX-01: Evaxion Biotech

• CAN-2409: Candel Therapeutics

• AST-301: Aston Sci

• EVX-02: Evaxion Biotech

Discover more about therapies set to grab major Cancer Vaccines market share @ Cancer Vaccines Treatment Market

Cancer Vaccines Market Drivers

• Rising Global Cancer Burden: The increasing incidence and prevalence of various cancers worldwide are driving demand for innovative preventive and therapeutic cancer vaccines.

• Advancements in Immuno-Oncology: Rapid progress in immunotherapy, including personalized neoantigen vaccines, mRNA vaccine platforms, and dendritic cell-based therapies, is expanding the cancer vaccines market.

• Growing Investment in R&D: Pharmaceutical and biotechnology companies are significantly increasing investments in cancer vaccine research, supported by strategic collaborations, licensing agreements, and public funding.

• Success of mRNA Technology: The clinical success of mRNA platforms has accelerated the development of personalized cancer vaccines, enabling faster vaccine design and manufacturing.

• Favorable Regulatory Incentives: Regulatory designations such as Orphan Drug, Fast Track, Breakthrough Therapy, and Priority Review are encouraging the development and commercialization of novel cancer vaccines.

Cancer Vaccines Market Barriers

• Complex Tumor Biology: Tumor heterogeneity, immune evasion mechanisms, and variations in patient immune responses make the development of effective cancer vaccines highly challenging.

• High Development Costs: Cancer vaccine research involves substantial investments in biomarker identification, clinical trials, manufacturing, and regulatory compliance, increasing overall development expenses.

• Lengthy Clinical Development Timelines: Demonstrating long-term efficacy, survival benefits, and immune response often requires extended clinical trials, delaying product commercialization.

• Manufacturing and Scalability Challenges: Personalized cancer vaccines require complex, patient-specific manufacturing processes, limiting scalability and increasing production costs.

• Limited Clinical Success Rates: Despite a growing pipeline, many investigational cancer vaccines fail to demonstrate significant efficacy in late-stage clinical trials.

Scope of the Cancer Vaccines Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others

• Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others

• Cancer Vaccines Therapeutic Assessment: Cancer Vaccines current marketed and Cancer Vaccines emerging therapies

• Cancer Vaccines Market Dynamics: Cancer Vaccines market drivers and Cancer Vaccines market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cancer Vaccines Unmet Needs, KOL’s views, Analyst’s views, Cancer Vaccines Market Access and Reimbursement

To know more about Cancer Vaccines companies working in the treatment market, visit @ Cancer Vaccines Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cancer Vaccines Market Report Introduction

2. Executive Summary for Cancer Vaccines

3. SWOT analysis of Cancer Vaccines

4. Cancer Vaccines Patient Share (%) Overview at a Glance

5. Cancer Vaccines Market Overview at a Glance

6. Cancer Vaccines Disease Background and Overview

7. Cancer Vaccines Epidemiology and Patient Population

8. Country-Specific Patient Population of Cancer Vaccines

9. Cancer Vaccines Current Treatment and Medical Practices

10. Cancer Vaccines Unmet Needs

11. Cancer Vaccines Emerging Therapies

12. Cancer Vaccines Market Outlook

13. Country-Wise Cancer Vaccines Market Analysis (2020–2034)

14. Cancer Vaccines Market Access and Reimbursement of Therapies

15. Cancer Vaccines Market Drivers

16. Cancer Vaccines Market Barriers

17. Cancer Vaccines Appendix

18. Cancer Vaccines Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/